This patent discloses peptides that specifically inhibit proliferation of epidermal and/or epithelial stem cells. On the one hand this patent is useful for protection of such stem cells when the patient is treated with a cytotoxic agent that targets proliferating cells, such as in the case of cancer therapy. On the other hand, this patent may be used in combination with other patents or...
This patent teaches the in vivo use of dithiocarbamate for hematopoietic reconstitution after bone marrow transplantation or myelosuppression. The dithiocarbamate or its analogs that are mentioned in the patent may be administered systemically without adverse effects.
This patent was used to argue that the WARF patents were anticipated. The patent has two independent claims. The first covering a method of isolating embryonic stem cells, and the second covering a method of maintaining embryonic stem cells. Both independent claims use leukemia inhibitory factor to allow for the ex vivo growth of stem cells without loss of...
This patent is a novel way to expand bone marrow cells ex vivo through contacting the bone marrow with a family of compounds. The single issued independent claim covers "A method for the transplantation of bone marrow cells" and the method involved contacting with a specific family of compounds. The first dependent claim states one member of this family of compounds as being...
Bryostatin is a drug derived from a type of symbiont bacteria. Although bryostatin has been used in clinical trials for oncology, results have not been excellent. This patent teaches that bryostatin and various derivatives thereof are useful for stimulation of hematopoietic stem cell proliferation. It will be interesting to see if bryostatin works on stimulating stem cell activity of...
This patent covers the composition of matter for several compounds and family of compounds that increase hematopoiesis. The compounds which are oxpurine nucleosides and their congeners, and acyl derivatives are demonstrated to accelerate hematopoietic reconstitution in both chemotherapy and irradiation induced suppression mouse models. In total the patent has over 70 examples. The...
Small molecules are provided that stimulate hematopoietic stem cell proliferation. These molecules may be of interest for stimulation of non-hematopoietic stem cells.
This patent teaches the use of IL-7 for stimulation of hematopoiesis, as well as increasing the output of lymphocytes. IL-7 has several interesting properties, including the ability to support homeostatic expansion of T cells.
This patent covers the use of IL-7 to stimulate hematopoiesis.
This patent covers a specific DNA enhancer sequence that is activated uniquely in embryonic stem cells. Such an enhancer is useful for numerous genetic engineering techniques, as well as, I believe, for generation of transgenic animals.